Aprea Therapeutics Adds New Investor to Series C Financing

Janus Henderson Investors joins Investor Group BOSTON and STOCKHOLM, Feb. 27, 2019 -- (Healthcare Sales &Marketing Network) -- Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor sup... Biopharmaceuticals, Oncology, Venture Capital Aprea Therapeutics, p53, myelodysplastic syndromes
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

We present the second case of PNGD leading to diagnosis of Hodgkin lymphoma. A 47-year-old woman presented with a new asymptomatic eruption of erythematous, nonscaly papules and thin plaques with variable annular configuration, symmetrically distributed on extremities. Biopsies revealed mid-dermal focal degeneration of collagen and leukocytoclasis in association with a palisaded mixed inflammatory infiltrate of neutrophils, lymphocytes, and histiocytes, some forming small granulomas. She had associated fevers, night sweats, weight loss, arthralgias and malaise. Imaging revealed retroperitoneal adenopathy. Excisional lymph ...
Source: The American Journal of Dermatopathology - Category: Pathology Tags: Extraordinary Case Report Source Type: research
Publication date: Available online 18 October 2019Source: Best Practice &Research Clinical HaematologyAuthor(s): David P. SteensmaAbstractPatients diagnosed with myelodysplastic syndromes (MDS) often ask their physicians whether earlier detection of disease or more prompt initiation of treatment might have resulted in a better outcome. The concept of starting therapy at an early point in the disease process when the clonal burden of abnormal hematopoietic stem cells may be lower and somatic mutational complexity less, and therefore treatment more likely to be effective, is attractive. However, at present there is no ev...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Publication date: Available online 18 October 2019Source: Blood Cells, Molecules, and DiseasesAuthor(s): Rosa Ruchlemer, Moshe Mittelman, Ari ZimranAbstractGaucher disease is an inherited lysosomal storage disease commonly associated with hepatosplenomegaly and cytopenias. Progressive cytopenias may be interpreted as an indication of advanced disease and suggest the need to start Gaucher disease specific treatment. As bone marrow evaluation is not routinely performed in Gaucher disease, other causes of cytopenias such as myelodysplastic syndrome a stem cell disorder may be missed. Six patients are described who suffered si...
Source: Blood Cells, Molecules, and Diseases - Category: Hematology Source Type: research
CONCLUSIONS: The short shelf life of platelets makes providing ABO-compatible platelets a challenge, and many institutions issue ABO-incompatible platelets when compatible units are not available. It is presumed that ABO antibodies that exist in donor plasma are diluted when platelets from multiple donors are combined to make a pooled product for transfusion. We present a case of a hemolytic transfusion reaction in a 73-year-old man with myelodysplastic syndrome who received an ABO-incompatible pooled platelet unit. This case report demonstrates that the dilution theory is not always true for pooled platelet units, and any...
Source: Immunohematology - Category: Hematology Tags: Immunohematology Source Type: research
Acute myeloid leukemia (AML) represents 80% of adult leukemias and 15–20% of childhood leukemias. AML are characterized by the presence of 20% blasts or more in the bone marrow, or defining cytogenetic abnormalities. Laboratory diagnoses of myelodysplastic syndromes (MDS) depend on morphological changes based on dysplasia in peripheral blood and bone marrow, including peripheral blood smears, bone marrow aspirate smears, and bone marrow biopsies. As leukemic cells are not functional, the patient develops anemia, neutropenia, and thrombocytopenia, leading to fatigue, recurrent infections, and hemorrhage. The genetic b...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Leukemia, Published online: 17 October 2019; doi:10.1038/s41375-019-0601-yLarge granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome
Source: Leukemia - Category: Hematology Authors: Source Type: research
Conditions:   Acute Myeloid Leukemia;   Blasts More Than 10 Percent of Bone Marrow Nucleated Cells;   High Risk Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   Refractory Myelodysplastic Syndrome Interventions:   Drug: Liposome-encapsulated Daunorubicin-Cytarabine;   Drug: Quizartinib Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 13 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Lindsay Wilde, Jonathan PanAbstractAnemia is the most common cytopenia seen in the myelodysplastic syndromes (MDS). The majority of patients with MDS will require red blood cell (RBC) transfusions during the course of their disease. However, unlike many other disease groups, there is no consensus on the optimal strategy for RBC transfusion in this patient population. In this article, we review the data supporting the use of restrictive transfusion strategies in multiple patient populations and discuss the current lite...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionA shared molecular mechanism accounting for the pathogenesis of inflammation in SchS remains elusive. Clonal hematopoiesis is not associated with other somatic mutations found in individuals with SchS or aCAPS.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Brief Report Source Type: research
Anemia is the most common cytopenia seen in the myelodysplastic syndromes (MDS). The majority of patients with MDS will require red blood cell (RBC) transfusions during the course of their disease. However, unlike many other disease groups, there is no consensus on the optimal strategy for RBC transfusion in this patient population. In this article, we review the data supporting the use of restrictive transfusion strategies in multiple patient populations and discuss the current literature regarding transfusion management in patients with MDS.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
More News: Biotechnology | Cancer & Oncology | Marketing | Myelodysplastic Syndrome | Pharmaceuticals | Venture Capital